Federal recordOn the record.
On the record.
In writing.
Selected milestones from the company’s reported CMS and FDA engagement. Read the date, the action and what it establishes.
Company-reported history. Participation, correspondence and receipt do not establish agency endorsement, product approval or reimbursement. No formal tribal consultation is claimed.
Strengthen, not diminish
The Tribes behind Rampart™ DL Matrix call for Government-to-Government consultation on Medicare skin-substitute policy.
Read the release↗FDA public testimony
Three public testimony sessions.
Explore the context↗Written FDA docket comments
Comments to FDA-2025-N-6895; supplemental comments followed on July 23.
Explore the context↗Government-to-government receipt
CHP reports receipt confirmation for its post-market evidence submission.
Explore the context↗Q4347 company listed as “Tribal”
A historical CMS pricing-list entry.
Explore the context↗Post-market evidence submitted
Materials report submission to CMS and all seven Medicare Administrative Contractors.
Explore the context↗Sovereign submission posted
The Physician Fee Schedule submission was posted on Regulations.gov.
910-page PFS comment
Company-reported comment on the CY 2026 Physician Fee Schedule proposed rule.
Meeting hosted by the Division of Tribal Affairs
Described as a meeting, not a formal tribal consultation.
HEAL WELL. AGE WELL. LIVE LONGER.